Podcasts about Chief scientific officer

In this episode, we sit down with Dr. Mark Esser, the inaugural Chief Scientific Officer of UVA's new Paul and Diane Manning Institute of Biotechnology. Dr. Esser, a renowned expert in immunology and vaccine development, shares his journey from AstraZeneca to leading this ambitious institute. With a vision to revolutionize healthcare and accelerate the development of life-saving treatments, Mark discusses fostering innovation, attracting biotech companies to Virginia, and the future of personalized medicine.

In this episode of The Pet Food Science Podcast Show, Lars Reimann and Kari Nichols from Eurofins Scientific explain the science behind analytical testing and regulatory compliance in the pet food world. They talk through the new label modernization rules, why ingredient consistency matters, and what makes testing fiber and shelf life so tricky. You'll also hear how lab methods are adapting to keep up with industry demands. Tune in now on your favorite podcast platform!"Crude fiber remains a necessary component in determining calories from carbohydrates, despite no longer being listed on pet food product labels." - Kari NicholsMeet the guests: Lars Reimann, Chief Scientific Officer at Eurofins Scientific, brings over 35 years of experience helping pet food clients navigate analytical, nutritional, and regulatory testing.Kari Nichols, Vertical Business Development Manager for Pet & Animal Nutrition, has 11 years of experience in lab services, specializing in food safety and label compliance.Dr. James Templeman & Lindsay Meyers: Raw Pet Food | Ep. 96Liked this one? Don't stop now — Here's what we think you'll love!What will you learn:(00:00) Highlight(01:01) Introduction(03:37) Labeling regulation changes(06:00) Dietary vs crude fiber(12:54) Fiber testing methods(28:49) Analytical methods matter(36:57) Shelf life evaluations(42:47) Final QuestionsThe Pet Food Science Podcast Show is trusted and supported by innovative companies like:* Trouw Nutrition* Kemin- EW Nutrition- Wilbur-Ellis Nutrition- ICC- Biorigin- Scoular

In this episode of Inside Matters, I'm joined by Dr Johan van Hylckama Vlieg, Chief Scientific Officer at Freya Biosciences. As a global leader in microbiome research, Freya is pioneering innovative approaches to women's health through biotherapeutics that are rooted in groundbreaking microbiome science. 00:00 Introduction to Dr. Johan van Hylckama Vlieg and Freya Biosciences 01:39 The Potential of the Microbiome 03:08 Challenges in Translating Microbiome Science to Treatments 05:29 The Rise and Fall of Microbiome Hype 08:58 Immunotherapy and the Microbiome 20:37 Women's Health and the Microbiome 35:01 Tools for Measuring Vaginal Dysbiosis 35:31 Intervention Studies and Donor Programs 36:23 Engraftment and Immune Response 37:39 Strain-Level Analysis and Engraftome 39:08 Vaginal Microbial Transplantation 44:13 Single Strain vs. Consortia 47:15 Freya's Development and Future Vision 50:04 Lessons from Kaleido 01:00:47 The Gates Foundation and Global Health 01:03:45 Predictions for the Microbiome Field A Hidden World with Huge Potential Dr van Hylckama Vlieg has spent more than 20 years exploring the vast and complex world of the microbiome — the trillions of microbes that live in and on our bodies. These tiny organisms play a huge role in our health. Over time, science has moved from simply identifying these microbes to understanding how they influence our immune system, metabolism and overall wellbeing. Yet despite this progress, turning those discoveries into real treatments remains a challenge. Dr van Hylckama Vlieg explained that while the science is compelling, the industry needs solid clinical data to bring investors and pharmaceutical companies on board. He sees microbiome-based immunotherapy as a particularly exciting area where transformative breakthroughs could lie ahead. Why Women's Health Matters Freya Biosciences has chosen to focus on the female reproductive tract — a part of the body where the microbiome is less complex than in the gut but just as important. Dr van Hylckama Vlieg spoke about the key role of lactobacilli in maintaining vaginal health. When these helpful bacteria are dominant, they protect against infections and support fertility. When the balance is lost, a state known as dysbiosis, the risks rise significantly. He also highlighted a wider issue — the historical lack of funding and focus on women's health. This is something Freya and others in the field are determined to change, and their research is already moving things in the right direction. A Bold New Treatment: Vaginal Microbiota Transplantation One of Freya's most innovative developments is vaginal microbiota transplantation or VMT. Inspired by the success of faecal microbiota transplants for gut health, this approach involves transferring a healthy vaginal microbiome into someone with dysbiosis. Early results are promising. Many women show a successful shift to a healthier microbial state. Looking ahead, the goal is to leverage the successes of these natural transfers and develop targeted microbial treatments that can be scaled up. This could lead to safe and widely available therapies that restore balance and improve reproductive health. Challenges and the Road Ahead Reflecting on his previous experience at Kaleido, another microbiome venture, Dr van Hylckama Vlieg spoke about the need for strong links between science, clinical design and commercial strategy. Though Kaleido faced setbacks, the underlying science remains solid and is being explored by others in the field. His outlook remains positive. With more trials underway and deeper understanding of how microbiomes influence disease, there is hope that these therapies will move from the lab into everyday medicine. Particularly in areas like immunotherapy, the potential to address root causes rather than just symptoms could be a game-changer. Final Thoughts Dr van Hylckama Vlieg's insights offer a compelling look into a rapidly evolving area of science. As researchers and companies like Freya push forward, the possibilities for transforming healthcare through the microbiome are growing fast. From improving fertility to preventing infections, these tiny organisms may hold the key to better outcomes for millions — especially in areas of health that have long been underserved.

Dom talks with Dr Rob Kelly, Chief Scientific Officer at TEO, about its Ovitage product, a bioactive protein made from sheep and lamb skins that would otherwise go to landfill, its unique amino acid profile and its Everee Women range. Tune in daily for the latest and greatest REX rural content on your favourite streaming platform, visit rexonline.co.nz and follow us on Instagram, Facebook and LinkedIn for more.

Jackie von Salm, a chemist and Chief Scientific Officer at Psilera, shares her father Terry's journey with FTD. We loved how Jackie was so raw + honest about family dynamics, becoming Terry's POA in her 20s, and how she learned how to be direct + honest in how she felt and what she needed while caregiving. You can learn more about what she's up to at Psilera here. You can also hear us chat all about their Research Summit this year on Patreon - along with an extended version of this episode.Patreon⁠⁠⁠⁠⁠ - join us ⁠⁠⁠⁠⁠www.patreon.com/remembermecommunity⁠⁠⁠⁠⁠ - you get exclusive content and it's a great way to support the show!----------Special thank you to today's sponsor ⁠⁠AVIADOBIO⁠⁠.If you're curious about anything RM, we'd love to connect with you on ⁠⁠⁠⁠⁠⁠⁠⁠Instagram, and visit ⁠⁠⁠⁠⁠our website at⁠⁠⁠⁠⁠⁠⁠⁠ www.remembermeftd.com⁠⁠⁠⁠⁠⁠⁠⁠, all the latest updates! ------Remember Me Podcast + Community is here to offer hope + human connection for families, caregivers, and individuals impacted by Frontotemporal Dementia (FTD). Always, always accept the good.

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Download the transcript here

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Listen to the podcast here

On this week's Tech Nation, Moira speaks with Warren Berger, author of  “A More Beautiful Question … The Power of Inquiry to Spark Breakthrough Ideas”, now in its tenth anniversary re-release and update. Then, Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics, tells us about how a treatment can turn into a vaccine and potentially provide long-lasting protection against cancer.

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors. Citylabs 4.0, now open in the heart of Manchester's Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organisations into close, purposeful proximity, providing a structural foundation for collaboration at scale. In this special live recording of the pharmaphorum podcast, developed in association with Bruntwood SciTech, Bruntwood SciTech's CSO Dr Kath Mackay, Manchester University NHS Foundation Trust T's Dr Katherine Boylan, and Dr Gillian Dalgliesh from QIAGEN join Deep Dive editor Eloise McLennan onstage at the opening of Citylabs 4.0 to discuss innovation in life sciences and the role of Greater Manchester in accelerating research, industry collaboration, and real-world evidence generation. Join us as we examine how this deliberate integration of healthcare stakeholders in Manchester is establishing new standards for collaboration and advancing patient outcomes through structured knowledge exchange. About the interviewees Dr Kath Mackay Kath Mackay is Chief Scientific Officer of Bruntwood SciTech - a JV between leading property developer Bruntwood, Legal & General, and Greater Manchester Pension Fund - the UK's leading creator and developer of innovation districts driving growth of the UK science and technology sector.  She has a keen interest in growing businesses and infrastructure within the sector, ensuring the UK is the best place to establish and scale a science and tech organisation.   Dr Mackay joined Bruntwood SciTech from the executive board of Innovate UK where she led the team responsible for growing businesses working in the biomedical, health, agriculture, and food sectors, creating and delivering a £800m portfolio of infrastructure, Catapults, grant and loan investments. She is also non-executive director of the Northern Health Science Alliance, the North of England's health partnership, and an elected fellow of the Royal Society of Biology. Dr Katherine Boylan Katherine is Director of Innovation at Manchester University NHS Foundation Trust (MFT), a position she has held since April 2020. This role involves overseeing innovation activities within MFT, as part of the wider Research and Innovation function. Innovation at MFT supports the whole pipeline from ideation, through to evidence generation, and ultimate implementation. She has been a member of the NICE Medical Technologies Advisory Committee since September 2020. Prior to this position, Dr Boylan worked in the University of Manchester for a number of years, most recently as Operations Director for the MRC funded Molecular Pathology Node, and the Trust-funded Diagnostics and Technology Accelerator. Dr Gillian L Dalgliesh, PhD Global Technical lead, Precision Diagnostics Gillian Dalgliesh has worked for QIAGEN for nine years and is based at their Manchester site, which is the global centre of excellence for molecular diagnostic development. QIAGEN partner with many drug companies to develop companion diagnostic (CDx) tests that enable clinical trials and subsequently launches of novel precision medicines. In recent years they have seen a real move beyond oncology into other disease areas such as immune, neurological and metabolic disorders. Dr Dalgliesh's role as global technical lead allows her to leverage her oncology precision medicine experience across the portfolio to bring precision diagnostic products to more patients. She has built her experience in precision medicine/oncology through not only her QIAGEN role but also through seven years working in precision medicine in AstraZeneca and prior to that working as part of the cancer genome project at the Sanger institute. Dr Dalgliesh is also an honorary senior lecturer at University of Manchester where she coordinates and delivers lectures for a QIAGEN sponsored BSc final year elective module ‘The Role of Diagnostics in Medicine'. This is part of a wider outreach role with the University and our NHS hospital. Through these roles she is keen to impact the local UK science community. About Bruntwood SciTech Bruntwood SciTech is the UK's largest dedicated property platform serving the growth of the nation's knowledge economy to become a global science and technology superpower. It is also the leading developer of city-wide innovation ecosystems and specialist environments, helping companies - particularly those in the science and technology sectors - to form, scale and grow A joint venture between Bruntwood, Legal & General and the Greater Manchester Pension Fund (GMPF), Bruntwood SciTech provides high quality office and laboratory space and tailored business support, offering unrivalled access to finance, talent and markets, an extensive clinical, academic and public partner network and a sector-specialist community of more than 1100 companies. Bruntwood SciTech is experienced in creating and developing strategic partnerships with UK regional cities, universities and NHS Trusts to drive economic growth. Its unique structure and funding vehicle more easily deploys long-term patient capital in innovation infrastructure, ensuring local economic benefit and growth. Valued at £1.5bn, Bruntwood SciTech has a portfolio of 5.2m sq ft across 11 campus locations and 31 city centre innovation hubs in Manchester, Cheshire, Birmingham, Leeds, Liverpool, Cambridge and London. It has plans to create a £5bn portfolio by 2033 and has a 2.3m sq ft secured development pipeline. Its campus locations include Alderley Park in Cheshire; West Village in Leeds; Innovation Birmingham; Birmingham Health Innovation Campus in partnership with the University of Birmingham; Melbourn Science Park in Cambridgeshire; Liverpool Science Park as a shareholder in Sciontec Liverpool; White City Deep Tech Campus in partnership with Imperial College London; and a cluster in the heart of Manchester's Oxford Road Corridor knowledge quarter - Manchester Science Park, Citylabs in partnership with Manchester University NHS Foundation Trust (MFT), Circle Square - a joint venture with Vita Group; and the £1.7bn JV partnership with The University of Manchester - Sister, formerly known as IDManchester. Its city centre innovation hubs include Bloc, Bond, 111 Piccadilly, Pall Mall and Manchester One in Manchester; Platform in Leeds; Cornerblock and Centre City in Birmingham; and The Plaza in Liverpool. Website / Twitter / LinkedIn / Instagram

Are wellness retreats just luxury getaways, or can they transform your health? In this episode of the Habits and Hustle podcast, I speak with Dr. Vishal Patel, who explains how most wellness gadgets might be causing more stress than health benefits.  We explore the science behind Sensei's approach, including how thermal imaging can detect muscular imbalances before they cause pain, and why most saunas aren't hot enough to deliver benefits. Dr. Patel debunks popular wellness myths, shares why foot strength is the foundation of longevity, and explains why tracking obsession can be counterproductive.  Dr. Vishal Patel is the Chief Scientific Officer at Sensei, a wellness retreat company co-founded by Larry Ellison and Dr. David Agus. With a background as a physician with a PhD in genetics, Dr. Patel combines Western medicine with Eastern practices like Ayurveda to create evidence-based wellness approaches that focus on personalization rather than rigid rules. What We Discuss:  03:02 Personalized Wellness Programs 05:51 The Science of Eating and Nourishment 08:56 Understanding Body Mechanics for Longevity 12:03 Vishal Patel's Background and Expertise 14:54 Debunking Wellness Myths and Misinformation 20:13 The Science Behind Wellness Trends 25:14 Exploring Infrared Saunas and Their Efficacy 30:00 The Role of Data in Health Tracking 35:29 Understanding Plasmapheresis and Its Implications …and more! Thank you to our sponsors: Therasage: Head over to therasage.com and use code Be Bold for 15% off  TruNiagen: Head over to truniagen.com and use code HUSTLE20 to get $20 off any purchase over $100. Magic Mind: Head over to www.magicmind.com/jen and use code Jen at checkout. Air Doctor: Go to airdoctorpro.com and use promo code HUSTLE for up to $300 off and a 3-year warranty on air purifiers.  Bio.me: Link to daily prebiotic fiber here, code Jennifer20 for 20% off.  David: Buy 4, get the 5th free at davidprotein.com/habitsandhustle.   Find more from Jen:  Website: https://www.jennifercohen.com/ Instagram: @therealjencohen   Books: https://www.jennifercohen.com/books Speaking: https://www.jennifercohen.com/speaking-engagement Find more from Dr. Vishal Patel: Website: https://sensei.com/  LinkedIn: https://www.linkedin.com/in/vishal-n-patel-md-phd/ 

In this episode of the "Metabolic Freedom Podcast," host Ben Azadi sits down with Alessandra Zonari, who is the co-founder and Chief Scientific Officer of OneSkin. They explore the fascinating science behind skin aging, particularly focusing on senescent cells, often referred to as "zombie" cells. These cells tend to build up as we age and play a significant role in skin deterioration. Alessandra shares insights into OneSkin's groundbreaking approach, which involves using the OS1 peptide to reduce these cells and promote healthier skin. They also discuss why it's crucial to have scientific evidence backing skincare products, how lifestyle and environmental factors can affect skin health, and the advantages of using non-toxic ingredients. The episode highlights the importance of making informed skincare choices for overall well-being.

Today we have Dr. Michael A. Schmidt, the founder, CEO, and Chief Scientific Officer of Sovaris Aerospace, a company focused on assessments and solutions applied to humans in space and extreme environments on Earth.  Michael is also a professor of aerospace medicine at the University of Central Florida College of Medicine, one of the few programs in the U.S. that offers a medical residency in aerospace medicine. Michael is known for his work pioneering the field of precision medicine. He uses molecular analytics, coupled with physiologic and behavioral assessments, to facilitate human performance and resilience on Earth as well as in the extreme environment of space. His work covers a spectrum from NASA, the NFL, the NBA, U.S. Olympic teams, Nike, SpaceX, Axiom Space, NASCAR, Special Operations, the Naval Submarine Medical Research Lab, the Mayo Clinic, and others. We had a long and fascinating conversation with Michael and decided to break the interview into two parts. This episode focuses on Michael's background and the cognitive and physical challenges astronauts experience in spaceflight. We also dive into the many ways that precision medicine is facilitating human performance and resilience here on Earth. In part two of our conversation, Michael talks about his work with NASA and SpaceX on the challenges of civilian spaceflight and the future of Mars exploration, including the construction of permanent colonies on the Moon and Mars. You won't want to miss that conversation. Show notes: [00:03:59] Dawn opens our interview mentioning that Michael grew up in Minnesota in a small farming community, asking if it's true that he sometimes had to do chores in 20- to 30-degree weather. [00:06:50] Dawn asks if it is true that Michael fell in love with science at a young age, even building telescopes at the age of 11. [00:08:00] Dawn asks Michael what it was that led him to become so fascinated with space specifically. [00:08:58] Dawn asks if Michael ever thought about becoming an astronaut. [00:10:09] Ken asks if it is true that Michael was a big reader as a child. [00:11:21] Dawn asks Michael to talk about his childhood athletic interests. [00:11:55] Dawn asks how it was that a high school quarterback from a small town in Minnesota ended up at university in the United Kingdom. [00:13:38] Ken asks Michael what years he worked at NASA Ames Research Center. [00:14:51] Ken mentions that when Michael was at NASA Ames, he did work collecting molecular and physiologic assessments of humans using NASA's 20-G centrifuge. Ken asks Michael to talk about the centrifuge and how he used it in his studies of hypergravity. [00:17:49] Ken comments on the fact that pieces of equipment like NASA's 20-G centrifuge are a precious scientific resource, and when they cease functioning, unfortunately, they are unlikely to be replaced. [00:19:40] Ken and Michael discuss the fact that microgravity, despite being one of the most pressing effects on astronaut health, is the one of the least addressed problems in human spaceflight. [00:21:48] Ken explains that Michael is the founder, CEO and Chief Scientific Officer of a company called Sovaris Aerospace, which is focused on assessments and solutions applied to humans in space and extreme environments on Earth. Ken asks Michael where the idea came from to found this company. [00:24:35] Dawn explains that since the human genome was first sequenced, there has been an acceleration of genome-based technologies that have made it possible to consider a person's genetic makeup, both in healthcare and optimizing performance. Dawn asks Michael to talk about the work he does applying genomics to human spaceflight. [00:28:52] Dawn asks about Michael's direction of the molecular profiling and precision medicine efforts for the Golden State Warriors during their record-breaking 73-9 season [00:32:57] Dawn mentions that Michael published a review in the journal Meta...

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. Visit twc.health/GRUBER and use Promo Code: GRUBER Secretary Kennedy announced the removal of the COVID vaccine from the CDC's recommended schedule, for 'healthy children and healthy pregnant women."

All Home Care Matters and our host, Lance A. Slatton were honored to welcome the team behind the Dementia Care Family Support Program.   About Denise M. Brown:   Denise began supporting family caregivers in 1990, launching one of the first online caregiving communities in 1996. She trains Caregiving Consultants, Facilitators, Guides and Navigators. She cared for her father for almost 20 years and for her mother for 8 years.   She's written 16 books for current and former family caregivers.    About Dr. Laura Gitlin:   Dr. Laura Gitlin is the Co-founder and Chief Scientific Officer at Plans4Care. She is an intervention scientist with over 40 years of experience in dementia care and research. Dr. Gitlin currently serves as a multiple Principal Investigator on several NIH-funded grants, where she leads the development and testing of innovative interventions to support people living with dementia and their caregivers.   About Eric Jutkowitz, PhD:   Eric Jutkowitz, PhD is the Co-founder and CEO of Plans4Care. He is health services focused on improving the nation's long-term care system. He co-founded Plans4Care to bring evidence-based dementia care out of the university and into the hands of all family caregivers.   About the Dementia Care Family Support Program:   Our Certified Caregiving Consultants partnered with Plans4Care, a technology start-up to offer 5 coaching sessions to dementia family caregivers in order to resolve 3 care challenges.   We'll share what we learned about using technology during coaching sessions, the common care challenges we addressed and the insights we gained from tracking our coaching sessions. We also will talk about what we learned about how to best support dementia family caregivers to help ease their stress and worries.

What does it take to challenge the deadliest brain tumors with sound waves? How do you scale a medtech startup into a multinational clinical company? And what advice can a top neuro-oncology innovator offer to those hoping to follow a similar path? Welcome to Neurocareers: Doing the Impossible! — The podcast where we explore the extraordinary journeys of those advancing the future of neuroscience and neurotechnology. I'm your host, Dr. Milena Korostenskaja. Today we're speaking with Dr. Michael Canney, the Chief Scientific Officer at Carthera, a clinical-stage medtech company revolutionizing brain therapy through therapeutic ultrasound. With over 15 years of experience in MedTech innovation, Dr. Canney specializes in glioblastoma, neurodegenerative diseases, and therapeutic ultrasound drug delivery. He's currently leading the SONOBIRD Phase 3 clinical trial across 40 sites in the U.S. and Europe, pushing the boundaries of what's possible in treating recurrent glioblastoma. Michael's career spans everything from FDA regulatory strategy to high-impact academic collaborations. He's co-authored over 50 peer-reviewed papers in top-tier journals and 14 patent families. But what truly drives him is improving patient outcomes and bringing hope to some of the most challenging areas in brain health. Whether you're curious about clinical trials, neuro-oncology innovations, or carving out your own career in medtech, this conversation is packed with insight and inspiration. Let's dive in! Chapters: 00:00:01 - Revolutionizing Brain Therapy with Ultrasound, Introducing Dr. Michael Canney 00:04:49 - Advancements in Ultrasound for Drug Delivery 00:10:15 - Innovative Ultrasound for Drug Delivery 00:13:49 - Innovative Ultrasound Approach for Tumor Treatment 00:16:02 - Understanding Blood-Brain Barrier Disruption 00:19:28 - Device Overview and Design Features 00:21:32 - Ultrasound Technology for Tumor Treatment 00:24:15 - Device Implantation in Cancer Treatment 00:28:34 - Challenges in Glioblastoma Treatment Trials 00:31:46 - Dr. Michael Canney's Journey into Ultrasound Research 00:36:15 - Starting a Postdoc Journey 00:39:20 - Career Development in Neuroscience 00:43:31 - Building a Startup Team 00:47:38 - Hiring for Clinical Application Specialists 00:52:16 - Growth of Careers in Neurotechnology 00:54:26 - Using AI in Clinical Trials 00:57:13 - Challenges in Medical Device Approval 00:59:41 - Overcoming Challenges in Medical Innovations 01:02:20 - Clinical Trials and Company Information About the Podcast Guest: Michael Canney, Ph.D., is Chief Scientific Officer at Carthera, a clinical-stage medtech company advancing brain therapy through innovative ultrasound-based devices. A co-author of more than 50 peer-reviewed articles, he specializes in neuro-oncology, glioblastoma and neurodegenerative diseases. At Carthera, he is responsible for leading scientific collaborations with academic institutions, organizing U.S. clinical trials and more. Connect with Dr. Canney on LinkedIn: https://www.linkedin.com/in/michael-canney-ph-d-42457b5/ Learn more about Carthera: https://carthera.eu/ Get familiar with the Sonobird clinical trial: https://sonobird.eu/ About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a career coach for people in neuroscience and neurotechnologies. As a professional coach with a background in neurotech and Brain-Computer Interfaces, Dr. K understands the unique challenges and opportunities job applicants face in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume, and cover letter development Neurotech / neuroscience job interview preparation and practice Networking strategies to connect with professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news  

On this episode of The Kara Goldin Show, we're joined by Catharine Arnston, Founder, CEO, and Chief Scientific Officer of ENERGYbits®—the pioneering brand bringing the power of algae to the forefront of wellness, energy, and longevity. After a deeply personal experience with a family health crisis, Catharine made it her mission to educate the world about the incredible health benefits of spirulina and chlorella—long before they became trendy.In our conversation, Catharine shares the early days of discovering algae's healing potential, what inspired her to build ENERGYbits, and why she believes algae is the most powerful superfood on the planet. We dive into the science behind spirulina and chlorella, the major obstacles she faced educating consumers, and how she's grown ENERGYbits into a trusted brand used by athletes, biohackers, and wellness seekers worldwide. Catharine also opens up about the resilience it takes to build a movement from scratch, the leadership lessons she's learned, and the habits that keep her going strong.Whether you're a health-focused founder, a nutrition enthusiast, or someone curious about building brands with real mission and impact, this episode is packed with insights you won't want to miss. Now on The Kara Goldin Show. Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks. To learn more about Catharine Arnston and ENERGYbits®:https://www.instagram.com/energybitshttps://www.linkedin.com/in/catharinearnstonhttps://www.youtube.com/energybitshttps://www.facebook.com/ENERGYbitshttps://www.twitter.com/energybitshttps://www.instagram.com/catharinearnston/https://www.energybits.com Sponsored By:Range Rover Sport - The Range Rover Sport is your perfect ride. Visit RangeRover.com/us/Sport and check it out. Check out our website to view this episode's show notes: https://karagoldin.com/podcast/692

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. twc.health/GRUBER. Promo Code GRUBER Saves 10% What came out at the WED May 21 Senate Hearing on Vaccine Myocarditis?

Blockchain Ireland's annual conference serving the blockchain, crypto and Web3 communities, Blockchain Ireland Summit 2025 kicks off this Friday. One of the speakers at the two day conference is Richard Blythman the Co-founder and Chief Scientific Officer of Naptha.AI, a startup building open, decentralised infrastructure for the next generation of AI. Richard's background is in machine learning, engineering, and academic research, and his work focuses on enabling developers to build intelligent agents that can work together, without relying on centralised platforms or Big Tech infrastructure. Ronan recently caught up with Richard. Richard talks about his background, the internet of agents, what naptha does, AI privacy, eu regulation and more.More about Richard Blythman:He previously co-founded Algovera, one of the earliest players in the decentralised AI sector, and holds a PhD in Engineering from Trinity College Dublin. His experience spans from building generative models and digital avatars in Big Tech, to leading research on fluid dynamics, multi-agent coordination, and privacy-preserving AI systems.At Naptha, Richard is exploring how decentralised agent networks could reshape everything from software development to data ownership, and why open standards like MCP are key to unlocking that future.

Today, we have another episode in our series of thoughtfully curated companies. This episode is sponsored by OneSkin, a company founded and led by an all-female team of PhD-level scientists. OneSkin is redefining how we think about aging, starting with the skin, our largest organ. I am delighted to introduce Dr. Alessandra Zonari as our guest today. Dr. Zonari is far from your typical scientist. She is a true visionary with a passion for longevity, skin regeneration, and an occasional karaoke jam. With degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Dr. Zonari brings a wealth of knowledge and a fresh perspective to our conversation today. Join us to learn more about OneSkin and how their products can reverse the effects of biological aging, helping your skin become stronger and more resilient as you age. IN THIS EPISODE YOU WILL LEARN: Dr. Zonari shares her mission to understand how skin can age healthier and stronger and reduce the risk of inflammation and diseases.  How the female-led research team at OneSkin brings a unique perspective to skincare How the OneSkin peptide can reverse 2.5 years of biological aging in just five days The unique way in which they test their products and measure biological aging at OneSkin  How estradiol loss during menopause exacerbates the accumulation of senescent cells and causes inflammation Some common misconceptions about skincare for women in perimenopause and menopause How lifestyle choices influence the aging process of the skin  Why we must protect the skin from environmental stressors to slow the aging process  How your skin cells can get reprogrammed to return to a youthful state How OneSkin developed a hair care line to address hair loss and thinning The importance of self-love and nourishing your body  ABOUT OneSkin:  Founded and led by an all-woman team of PhD-level scientists, OneSkin is transforming the way we think about aging, starting with the body's largest organ, the skin. Our proprietary OS-01 (oh ess one) peptide is the first ingredient to reverse the biological age of skin by targeting cellular senescence, a key driver of aging. By targeting cellular senescence, the OS-01 peptide switches off the damaged cells that contribute to lines, wrinkles, and sagging skin. The result? Skin that looks and behaves younger. Our products are designed for young and mature skin, because it is never too early or too late to invest in your skin health! We create next-level skin care. BIO: Alessandra Zonari, PhD, OneSkin Co-Founder & CSO Alessandra is not your typical scientist. She is a visionary with a passion for longevity, skin regeneration, and the occasional karaoke jam. Growing up in a close-knit family in Brazil, Alessandra saw her grandparents struggle with age-related diseases, and she soon became fascinated by the possibility of using stem cells to redefine the aging process. After earning degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Alessandra joined OneSkin in 2017 as a founding member and Chief Scientific Officer. Her contributions include 20+ papers, three patents, and the development of their proprietary OS-01 peptide. Connect with Cynthia Thurlow   Follow on X Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Alessandra Zonari On the ONESKIN website ONESKIN on Instagram Interested in trying OneSkin for yourself? Visit oneskin.co/CYNTHIA and use code CYNTHIA for 15% off your first purchase!

Prime Minister Mark Carney unveiled his new cabinet this week, but he won't be unveiling a budget this year — a move that drew plenty of criticism from his opponents. Newly appointed Industry Minister Melanie Joly joins The House to discuss the decision and weighs in on the new government's other economic priorities. Then, two Hill watchers offer their takes on whether Carney's cabinet picks deliver on his promise for change.Plus, weeks after the election, dramatic recounts are still underway in a handful of ridings, and those results could shake up the House of Commons even further. An elections expert explains what's happening and whether the flip-flopping risks undermining confidence in elections.Finally, measles cases are rising in some parts of the country and provinces are under fire for not doing enough to keep the public better informed. Two doctors talk to Catherine Cullen about what can happen when politics and a deadly disease collide.This episode features the voices of:Melanie Joly, Minister of IndustryShannon Proudfoot, writer for The Globe and Mail's Ottawa bureauPaul Wells, author and podcasterHolly Ann Garnett, associate professor of the Royal Military College of CanadaDr. James Talbot, former Chief Medical Officer of Health for AlbertaDr. Kumanan Wilson, Chief Scientific Officer of Bruyère Health Research Institute

Episode 051 | Greg Maguire, PhD is the Co-Founder of the SRM Living Foundry at UCSD in San Diego and the Co-Founder & Chief Scientific Officer of NeoGenesis, a wonderful company I talk with my patients about all the time. If you haven't yet listed to episode 047 featuring Christine Preston, that one pairs delightfully with my conversation with Dr. Maguire.Awarded a prestigious Fulbright-Fogarty Fellowship from the National Institutes of Health, Dr. Maguire managed his NIH funded laboratory at UCSD studying tissue degeneration and regeneration, and the role of stem cell released molecules (SRM) through paracrine and autocrine actions to maintain, repair, and regenerate human tissues. His NIH funded studies of systems biology and reverse engineering at UC Berkeley and stem cell biology at UC San Diego led to the development of adult stem cell-based S2RM® technology for the development of therapeutics and medical procedures.Dr. Maguire pursued his graduate training at the University of California, Berkeley, University of Houston, University of Texas, The Marine Biological Labs, Woods Hole, MA, and Cold Spring Harbor Laboratory, NY. He is a former professor of neuroscience and ophthalmology at the University of California, San Diego School of Medicine, a visiting associate professor of physiology at Keio University School of Medicine in Tokyo, Japan, visiting assistant professor of molecular neurobiology at the University of Washington, and a visiting scientist at Massachusetts General Hospital (MGH), at Harvard University.Dr. Maguire has over 100 publications and is currently working on his book entitled, “Spontaneous Stem Cell Healing”.The Above & Beyond Dermatology podcast is grateful to NeoGenesis for the great work they do and for their generous support of this episode. If you're a skin care professional and would like to learn more about helping your customers with NeoGenesis, click here to learn more. If you'd like to learn directly from the NeoGenesis team, text me at 715-391-9774 and I'll be happy to make a warm introduction.Connect with and learn from Greg Maguire & NeoGenesisLearn & Shop NeoGenesisDr. Maguire's Skin Care BlogNeoGenesis Wholesale Partnership for Medical ProfessionalsMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical research?” and “What spatial biology can tell us about disease and drug discovery”. In the first article, DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. In the second article, Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. In the third article, DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology's use in drug discovery and bettering our understanding of disease.

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Download the transcript here

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Listen to the podcast here

CareQuest Institute for Oral Health is a national nonprofit dedicated to creating an oral health care system that is accessible, equitable, and integrated. Learn more about how their advocacy, philanthropy, research, and education are creating a better oral health system at carequest.org/turnonthelights What happens when the power of large language models meets the complexity of modern medicine? In this episode, Eric Horvitz, Chief Scientific Officer of Microsoft, discusses the transformative impact of artificial intelligence in health care, particularly the shift from rule-based systems to data-driven models like GPT-4. He highlights how AI can reduce physician burnout by handling administrative tasks and supporting clinical decision-making. Eric emphasizes the importance of AI collaborating with, rather than replacing, health care professionals to improve diagnostic accuracy and patient safety. He also explores future possibilities, including personalized health companions, intelligent patient portals, and AI-powered tumor board simulations. Overall, he underscores both the exciting potential and the responsibility involved in integrating AI safely and meaningfully into health care. Tune in for a thought-provoking conversation on how AI is transforming health care, from easing clinician burden to reimagining patient care and medical decision-making! Learn more about your ad choices. Visit megaphone.fm/adchoices

Peter A McCullough, MD, MPH, Chief Scientific Officer, The Wellness Company  twc.health/GRUBER | Promo Code GRUBER Saves 10% Spaces Event TONIGHT (5/7) on The Steve Gruber Show X account  RFK Jr announces a new “Take Control of Your Health” campaign "We Need a Great Reset in Health" The need to stockpile prescription medication

We catch up on the tri news and racing from the weekend and give our thoughts on the announcement that the IM World Champs is moving back to Kona. Alison Heather is a former academic professor whose research has focused for over 24 years' on the physiology of steroid hormones and their role in health and disease. She has international recognition for her development of bioassays for the detection of steroid hormones. Alison acts as an advisor to many High Performance Sport Teams including those focusing on female athlete health, triathlon, cycling, running and sports supplements and is currently the Chief Scientific Officer for plasmaide In this conversation, we discuss the supplement Plasmaide, its origins and its benefits for athletes. Dr Heather explains the science behind nitric oxide production, the ingredients in Plasmaide and how it compares to other supplements like beetroot juice. The discussion covers both acute and chronic benefits of Plasmaide, its adaptogenic properties and its influence on carbohydrate metabolism. Dr. Heather also provides practical advice for using Plasmaide safely and effectively, emphasizing the importance of consulting with a healthcare professional before starting any new supplement regimen. (0:00:00) – A weekend of bike crashes (0:09:22) – T100 goes to the Gold Coast in 2026 (0:15:51) – The racing from IM703 Venice and IRONMAN Australia  (0:24:16) – IRONMAN World Champs moves back to Kona (0:40:05) – Dr Alison Heather intro (0:41:38) – Dr Alison Heather LINKS: Dr Alison Heather at https://www.insitugen.com/ Plasmaide at https://plasmaide.com.au/ Live Feisty podcast at https://livefeisty.com/podcasts/feistytriathlon/ironman-goes-backwards-special-world-champs-episode/ Pro Tri News podcast at https://protrinews.buzzsprout.com/1736374/episodes/17067560-episode-217-kona-is-back-with-ironman-ceo-scott-derue 2025 Oceania Triathlon Super-Sprint Championships Runaway Bay at  https://triathlon.org/events/2025-oceania-triathlon-super-sprint-championships-

This week on The Genetics Podcast, Patrick is joined by Madhuri Hegde, SVP and Chief Scientific Officer of Revvity. They discuss Revvity's advances in ultra-rapid clinical-grade sequencing, opportunities, challenges, and global inequities in newborn screening, and the dilemma of resequencing versus long-term data storage.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Madhuri01:52 Rebranding Revvity as a healthcare company02:51 Advancements in sequencing and Revvity's projects, including newborn screening tests and clinical ultra-rapid sequencing12:29 Opportunities and challenges for newborn sequencing and global inequity in access17:46 Price of sequencing and data storage versus resequencing considerations21:10 Complexities and nuances of genomic data interpretation23:28 Rethinking data portability and storage across the lifespan26:00 Understanding penetrance and population genetics through lifelong sequencing27:36 Scaling genetic counseling to match advancements and the potential value of chatbots32:45 The promise of proteomics and translating Olink data to the clinic 34:31 Implementing polygenic risk scores in clinical management  37:12 Transitioning from academia to industry and insights into product development38:37 Closing remarksFind out moreRevvity (https://www.revvity.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

Bioscience breakthroughs are transforming lives in Central Ohio. From cutting-edge gene therapies to world-first medical devices, the region's life sciences sector is booming—and saving lives. This week's Columbus Metropolitan Club forum brings together scientific leaders and business innovators to explore how research, investment, and clinical development are coming together to power the next generation of healthcare innovation.  Featuring:  Dr. Frank Agbogbo, Vice President of Process Development, Forge Biologics  Dr. Erandi De Silva, Investment Partner, Drive Capital  Dr. Louise Rodino-Klapac, Executive Vice President, Head of R&D, and Chief Scientific Officer, Sarepta  Robin Sears, President and CEO, LENTECHS  The host is Tyler Allchin, Managing Director, Healthcare, JobsOhio This forum was created in partnership with the 2025 COSI Science Festival, and was sponsored by: Armatus Bio, Battelle, Holder Construction, Ohio Life Sciences, The Ohio State University Wexner Medical Center, and Sarepta. The presenting sponsor of the CMC livestream was The Center for Human Kindness at the Columbus Foundation. Our livestream partner was The Columbus Dispatch. This forum was also supported by The Ellis. This forum was recorded before a live audience at The Ellis in Columbus' historic Italian Village on April 30, 2025. 

Episode Summary: In this deeply insightful episode, Dr. Nasha Winters is joined by renowned pediatric neurologist and researcher Dr. Richard Frye. With decades of experience and hundreds of peer-reviewed publications, Dr. Frye shares his groundbreaking work in autism spectrum disorder, particularly its links to mitochondrial dysfunction, neuroinflammation, and metabolic abnormalities.You'll learn how Dr. Frye's clinical and lab research is reshaping the narrative around autism—from a strictly genetic and behavioral model to a more hopeful, treatable biomedical framework.They dive into:The mitochondrial abnormalities often present in children with autismThe role of oxidative stress, folate transport issues, and methylationWhy nutrition and prenatal health matter more than everHow treatments like leucovorin, B12, CoQ10, and lifestyle changes can support better outcomesThe promising intersection of microbiome therapy, metabolic testing, and real-world clinical careThis is a must-listen for clinicians, caregivers, and anyone passionate about innovative approaches to autism care.Guest Bio:Dr Frye is a Harvard trained Child Neurologist who received both an MD and PhD from Georgetown University. Dr. Frye is a national leader in autism spectrum disorder (ASD) research, particularly metabolic disorders, and has authored over 300 publications. He has developed the Metabolic Learning Resource which has recently released The Folate Fix. He is President and Chief Scientific Officer of the Autism Discovery and Treatment Foundation, Chief Medical Officer of the Neurological Health Foundation, Director of Research and Neurologist at the Rossignol Medical Center.

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Listen to the podcast here

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the technologies must keep up with this to open that novel target space. That is problem number one." "So, as you know, AI has gotten a little bit of a bad reputation over the last few years, and there was a huge hype about this, and I want to be very clear about this. It takes more than 10,000 steps to make a medicine. At iBio, we enable three of these steps with generative AI. So, that does not make us an AI company. That does not make our molecules AI drugs. What it does is it actually makes it possible for us to create medicines that we couldn't do before. So, the way we use AI at iBio is multiplefold. First, we start our discovery process with the epitope steering engine. You have to imagine that drug targets are massive proteins, and only very small regions on these proteins have a biological function. So you want to get your antibody exactly to those regions that cause a biological function."  #iBio #DrugDiscovery #MedAI #Obesity #GLP1 #CardioMetabolicDiseases #Antibodies #AntibodyTherapies #Myostatin iBioinc.com Download the transcript here

Congressman Glenn Grothman from Wisconsin sheds light on the pressing issues surrounding immigration and judicial reform. Grothman discusses the alarming trend of unaccompanied migrant children going missing and criticizes the Democratic Party's stance on illegal immigration. He also addresses the challenges within the judiciary, highlighting concerns about radical judges and the impact of their decisions on American law. Additional interview with Dr. Peter McCullough, Chief Scientific Officer at The Wellness Company, who sounds the alarm on the rise of autism rates in America, as highlighted by HHS Secretary RFK Jr. and supported by new data. Finally, Senior policy analyst Andrés Martínez-Fernández from the Heritage Foundation provides insights on President Trump's recent meeting with El Salvador's President Nayib Bukele, focusing on their agreement to address the challenges of illegal immigration and criminal activity in the U.S.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, Dr. Scott Sigman sits down with Sarah Mayes, Ph.D., Chief Scientific Officer and Co-founder of Alafair Biosciences, and Dr. Eric Giza, Professor of Orthopaedic Surgery, Chief, Foot & Ankle Service, Co-Director, UC Davis/Reno Foot & Ankle Fellowship Head Team Physician, Sacramento Republic FC, UC Davis Department of Orthopaedic Surgery,  to discuss the journey behind VersaWrap Hydrogel Sheet. From its humble beginnings in a university lab to becoming an innovative solution for tendon and nerve protection, VersaWrap is redefining soft tissue healing. Sarah shares the entrepreneurial hurdles of bringing a medical device to market, while Dr. Giza provides a surgeon's perspective on how this cutting-edge product is impacting patient outcomes.

In Episode 34, join our founder, Danné Montague-King, alongside DMK's Chief Scientific Officer, Dr. Jayant Lokhande, as they dive deep into "Understanding Pigmentation in Melanated Skin."This episode is packed with essential information on:✅ Demystifying melanin—its science, roles, and unique characteristics in melanated skin.✅ Addressing and correcting common skincare myths surrounding deeper skin tones.✅ Detailed breakdown of pigmentation conditions like melasma and post-inflammatory hyperpigmentation (PIH).✅ DMK's revolutionary bio-inspired approach for safely treating pigmentation concerns.✅ Actionable, culturally-sensitive practices every skincare professional should incorporate.Instagram - Facebook - TikTok - Twitterwww.dannemking.com

Dr. Keshav K. Singh is the Joy and Bill Harbert Endowed Chair and Professor of Genetics, Dermatology and Pathology at the University of Alabama at Birmingham. He is also the founding Editor-in-Chief of the Mitochondrion Journal. In addition, Keshav is the founder and Chief Scientific Officer of the company Yuva Biosciences. Research in Keshav's lab focuses on how to reverse aging and diseases like cancer that are associated with aging. Mitochondria are relevant for all of the hallmarks of aging, including things like changes in epigenetic regulation, genomic instability, and communication problems between cells. He is working to better understand the intricacies of how mitochondria work and how they can be targeted or leveraged to improve health. Outside of work, Keshav enjoys flying kites on the beach, traveling, and painting. In particular, he gets creative painting all different kinds of mitochondria, and this is a great outlet for him when experiments aren't working in the lab. Keshav began his studies in India, earning his Bachelor of Science degree in microbiology from Rohilkhand University and his Master of Science from G.B. Pant University of Agriculture and Technology. Next, he moved to Australia and was awarded his Ph.D. in Marine Biology from the University of Wollongong. Keshav then conducted postdoctoral research at Harvard University before joining the faculty at Johns Hopkins University School of Medicine. He later moved to the Roswell Park Comprehensive Cancer Center and served as Distinguished Professor of Oncology. Next, he joined the faculty at the University of Alabama at Birmingham where he is today. He is a Fellow of the Royal Society of Medicine and a member of Sigma Xi (The Scientific Research Honor Society). He has been recognized as one of the Innovation Heroes by Newsweek, and Yuva Biosciences was the recipient of the "Company of the Year - Innovation and Excellence into Mitochondrial Science" award at the Indian Icon Awards. In our interview, Keshav shares more about his life and science.

EP 205: Catharine Arnston, founder and Chief Scientific Officer of ENERGYbits, is back for another fascinating conversation—this time focused on women's health, hormones, and the power of algae. We dive into how spirulina and chlorella support mitochondrial function, balance hormones, and deliver potent antioxidant benefits, all grounded in decades of research. Catharine's passion for algae began when her sister fell ill, sparking a journey that led to the creation of ENERGYbits. Her deep knowledge and infectious enthusiasm make this a must-listen for anyone curious about how a simple, sustainable superfood can make a big impact. Check Out ENERGYbits | Click Here & use code DRTYNA for 20% off Topics Discussed:  How does algae support women's hormonal health and balance? What are the benefits of spirulina and chlorella for mitochondrial function? Can algae help with symptoms of perimenopause and menopause? Why is algae considered one of the most nutrient-dense superfoods? How do antioxidants in algae improve overall health and energy levels? On This Episode We Cover:  00:00:00 - Introduction  00:02:20 - Manufacturing process  00:04:22 - Different types of algae  00:06:37 - Manufacturing process 00:12:49 - Vegan collagen  00:14:43 - Mitochondrial health & estrogen  00:19:32 - Perimenopause 00:26:11 - Women's aging & hormone health  00:28:49 - Estrogen levels  00:34:55 - Dr. Tyna's experience with ENERGYbits  00:38:04 - Carnivore diet & chlorophyll  00:40:50 - Red light  00:45:43 - B Vitamins & decision fatigue  00:47:31 - Constipation  00:49:53 - Aging and finding joy  00:56:04 - Testimonials  Further Listening:  EP. 139: Algae 101 | Catharine Arnston of Energy Bits Hormones Playlist Sponsored By: ENERGYbits | Click Here & use code DRTYNA for 20% off Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. twc.health/GRUBER. Promo Code GRUBER Saves 10%

The amount of time children and adolescents spend with a screen is absolutely stunning. Lots of people, including parents, health leaders, educators, elected leaders from both parties I might mention, and even children themselves, are highly concerned and are discussing what might be done about all this. I'm delighted to begin this series of podcasts on children and screen time. Today we're welcoming two very special guests who can talk about this topic in general, and especially about what's being done to protect children and adolescents. Several podcasts will follow this one that deal with food and nutrition in particular. Our first guest, Kris Perry, is Executive Director of Children and Screens, an organization devoted to protecting children. In the digital world by addressing media's impact on child development, communicating state-of-the-art information, and working with policymakers. Prior to joining children in Screens, Kris was senior advisor of the Governor of California and Deputy Secretary of the California Health and Human Services Agency. Our other guest, Dr. Dimitri Christakis is a professor of pediatrics at the University of Washington School of Medicine, and director of the Center for Child Health Behavior and Development at Seattle Children's. He's also editor-in-chief of JAMA Pediatrics and both Chief Scientific Officer and Chair of the Scientific Advisory Board of Children and Screens. He's also the co-editor of a new book that I'm very excited to discuss. Interview Summary Download The Handbook of Children and Screens: https://link.springer.com/book/10.1007/978-3-031-69362-5 Kris, let's start with you. Could you set the stage and give us some sense of how much time children spend in front of screens, children and adolescents, and what devices are being used and what kind of trends are you seeing? Yes, I'd be happy to. I had better news for your listeners, but as you might imagine, since the advent of the smartphone and social media, the youth digital media use has been increasing each year. Especially as children get older and have increasing demands on their time to use screens. But let's just start at the beginning of the lifespan and talk about kids under the age of two who shockingly are spending as much as two hours a day on screens. Most spend about 50 minutes, but there's a significant chunk spending up to two hours. And that rises to three or three to five hours in childhood. And eventually in adolescence, approximately eight and a half hours a day our adolescents are spending online. Also wanted to talk a little bit about middle childhood children, six to 12 years of age. 70% of them already have a social media account, and we all know social media wasn't designed for children. And there are restrictions on children under 13 using them, and yet children six to 12 most have an account already. Over half of four-year-olds have a tablet and two thirds of children have their own device by the age of eight; and 90% of teens. This probably won't be surprising, and yet we should really think about what this means; that 90% of teens are using YouTube, 60% are on TikTok and Instagram, and 55% use Snapchat. I'll stop by ending on a really alarming statistic. Oh my, there's more? There's more. I know it! I told you. I'll be the bearer of bad news so that we can talk about solutions later. But, children are checking their devices as often as 300 times per day. 300 times. 300 times per day, and we're talking about screen time right now. And we know that when you're using time to be on screens, you are not doing something else. And we know that childhood is full of challenges and skill building and mastery that requires repetition and tenacity and grit and effort. And the more children are on their screens, whether it's social media or other entertainment, they're not doing one of these other critical child development tasks. That's pretty amazing. And the fact that the older kids are spending more time on before a screen than they are in school is pretty alarming. And the younger, the really youngest kids, that's especially alarming. So, Dimitri, why should we fret about this? And I realize that fret is kind of a mild word here. Maybe all I'll panic would be better. But what are some of the major concerns? Well, I don't think panic is ever the right reaction, but the numbers Kris conveyed, you know, I think do paint a, let's say, concerning story. You know, the simple reality is that there's only so much time in a day. And if you think about it, teenagers in particular should sleep for eight to 10 hours a day at a minimum. They really should be in school six and a half, seven hours a day. And then when you add the numbers, Kris conveyed, you realize that something's giving because there isn't enough time left to spend eight and a half hours a day. The two things at a minimum that are giving are sleep. Kids are losing sleep to be on screens. And I'm sorry to say that they're losing school while they're on screens. We just published a paper that used passive sensing to see where and when children are on their screens. And found that the typical child in the United States spends an hour and a half during the school day on their device. And it's not, before any of your guests ask, on Wikipedia or Encyclopedia Britannica. It's on the usual suspects of social media, TikTok, etc. So, you know, we talk about displacement, and I think it's pretty obvious what's being displaced during school hours. Its time focused on learning if it's in the classroom, and time focused on being authentically present in real time and space if it's during recess. School hours are precious in that way, and I think it is concerning that they're spending that much time in school. And I told you the median. Of course, some kids are above that, a significant half of them are above it. And at the high end, they're spending 30 to 40% of school time on screens. Now, some schools have enacted policies. They don't typically enforce them very well. One of the things that drives me nuts, Kelly, is that as an academic, you know we love to argue amongst ourselves and hem and haw. And this issue about whether or not there's such a phenomenon as digital addiction is still being hotly debated. Honestly, the only behavioral addiction that's being seriously considered at this point is gaming disorder. The DSM-5 didn't consider gaming, considered it, but didn't include, it said it needed further study in 2013. In 2022, the WHO did include gaming disorder as an ICD-11 diagnosis. But just as further evidence how slow science is compared to technology., I mean gaming, while it's still an entity, represents a small fraction of most people's screen time. And the numbers that Kris conveyed, a small fraction of that for some on average was gaming. For some people, it's their screen use of choice, but for many, it's social media. YouTube, although I consider YouTube to be a social media, etc. And at the high end when you hear the numbers Kris conveyed in my mind that's a behavioral addiction any way you define it. Well, and if you think about things that we all agree are addictive, like nicotine and alcohol and heroin, people aren't doing it 300 times a day. So it's really pretty remarkable. And that's exactly right. One of the salient criteria for those addictions is that it's interfering with activities of daily living. Well, you can't be on a screen for nine hours a day when you're supposed to be asleep for 10 and at school for six without interfering with activities of day. The math isn't there. And things like being physically active and going out and playing. That's right. It doesn't add up. So, you don't need the DSM-5. You don't need a psychiatrist. You need a mathematician to tell you that there's too much time on this thing. Alright, so Kris, talk to us if you will, about the Children and Screens organization. I have a lot of respect for the organization and its work. Tell us how it got started and what its objectives are. Well, it's so great to be on this show with you and get to see you in your day job, Kelly. Because you've been an advisor, like Dimitri, to the institute almost since its inception, which is in 2013. As you know, our founder, Dr. Pamela Hurst-Della Pietra, really became concerned as a parent about the way digital media was impacting her children and sought out some answers. Well, what does this mean? Why is this happening? What should I do? And found out that this, of course, is 2013, this is a long time ago. There wasn't that much research yet. And it was multidisciplinary. In other words, there might be a study among neuroscientists or developmental psychologists, even ophthalmologists. But there really hadn't been, yet, a concerted effort to bring these different disciplines and the research together to try to answer some of these hard questions about the impact on kids. And lo and behold, here we are, almost 13 years since the advent of the smartphone and social media. And there is an astounding amount of research across disciplines. So, what we do at the institute is we try to translate it as fast as we can and make it actionable for parents, providers, and policy makers. And we do that through our Ask the Experts webinar series where we bring the experts themselves directly to our audience to talk about these impacts and answer questions. We also create printables, you might say, like tip sheets and Research at a Glance Digest, and newsletters and FAQs and we've upgraded our website to make it very navigable for parents of kids of all ages. I even started my own podcast this year, which has been really fun. Dimitri was my first guest, so it's great to see him here. And we have convenings. We're having our third Digital Media Developing Mind Scientific Congress this summer where the experts come together in person to discuss issues. And we really try to focus them on advancing research and supporting it, translating it, and positioning the issue as a policy priority. We'll be in Washington, DC where we know lawmakers are grappling with the impact of digital media on child development, how to make online, products safer for kids and protect their data. The Institute is in the middle of all of this, trying to facilitate more discussion, more results and more support for parents primarily. Kris, a couple of things occur to me. One is that the breadth of work you do is really very impressive because you're not only having very hands-on kind of in the real world ex advice for parents on how to navigate this world, but you have advice for and helpful resources for policy makers and for researchers and people. It's really quite an impressive breadth of work. The other thing that occurred to me is that I don't think you and I would have any podcast career at all if it hadn't been for Dimitri helping us out. So thanks Dimitri. Yeah. So, let me ask you, Dimitri, so I know that both you and Kris are committed to an evidence-based approach to making policy. Yeah. But technology advances way more quickly than scientists can evaluate it. Much less come up with policies to deal with it. And by the time research gets funded, completed, published, you're on to eight new levels of technology. So how does one handle this fundamental problem of pace? It's a really good question. I mean, I can tell you that we should at a minimum learn from the mistakes we've made in the past. And, you know, one of the most critical, frankly, that most people don't really understand is that we talk about the age at which children get social media accounts in this country. Kris pointed out that actually pre-teens routinely have social media accounts. Social media companies do very little to age gate. They're trying to do more now, but even the age at which we've accepted it is being normative is 13. Few people know where that comes from. That doesn't come from talking to pediatricians, psychologists, parents about what age is the appropriate age. It comes entirely from COPPA (Children's Online Privacy Protection Act), which basically was the original privacy act that said that before the age of 13, companies could not collect data from children. So, because these companies were interested in collecting data, they set the age at 13 so as to not have any constraints on the data they collected. Well, that's not even common sense-based policy, let alone evidence-based policy. And it's never been revisited since. It's very troubling to me. And as things move forward, I think we have to learn from those mistakes. Medicine has a maxim which is do no harm. We use that phrase a lot and I think it's a good one in this case. I think it's a particularly good one as we see the new technologies emerging around artificial intelligence. And you know, again, like any new technology, it has incredible upside. We made the mistake and we're still paying for it, about not appreciating the downsides of social network sites, and frankly, the internet in general. And I would hope we put guardrails in place now. And if you will apply the same standard we apply to other non-technology based products. You can't introduce a new pharmaceutical to anybody, let alone to children, until you show it's safe and effective. You can't bring toys to the world that are dangerous. Why do we have more safety precautions around toys than we do around websites for children? You know, a lot of it involves changing defaults, doesn't it? Because if the default is that government or somebody out there has to prove that something is harmful before it gets taken away. That changes everything then if you began at a different point where these companies have to prove that these things are safe. Correct. Or they're permitted. Then the companies would find workarounds and they would play games with that too, but at least that would help some. Well, it would help some. And at least we'd be philosophically in the right place. By the way, Kris didn't say it, so I'll say it. You know, the mission of Children and Screens, lest we sound like Luddites here, is not get kids away from technology. Take away their smartphones. We all recognize that technology is here to stay. I think all of us appreciate the incredible upside that it brings to children's lives. The mission of Children and Screens is to help children lead healthy lives in a digital world. And part of the reason she and I often talk about the concerns we have is because the pros make the case for themselves. I mean, you know, no one needs to come here and tell you how amazing it is that you could Google something or that you could get somewhere with GPS. I mean, we know it's amazing and we all rely on it. And none of us are ever talking about getting rid of that stuff. That makes good sense. It's like, you know, children benefit from the fact that they can get around with their parents in the automobile. But you want to have car seats in there to protect them. Exactly. And that's exactly right. There needs to be assurances of safety and they're none. I mean, they're really virtually none. The age getting is a joke. And even if we accept it as effective, the age set of 13 is too young, in my opinion. We started this conversation talking about these medias being addictive, I believe they're addictive. There are legitimate academics that will debate me on that, and I'm happy to join that debate. But as I said before, it's a tough argument to win when people spending upwards of 10 to 16 hours a day doing it. I don't know what you call that besides addictive. We can argue about what percentage are doing that, but nevertheless, once you accept something as addictive, for other addictive things we immediately age gate it above 18 or 21, right? Mm-hmm. We don't believe that the teenagers have the ability to regulate their alcohol or tobacco or gambling, all of which we accept are addictive. In fact, in the case of alcohol, we raised the age from 18 to 21 because we thought even 18-year-olds weren't able to do it. And yet somehow for this behavior, we think of it as just so different that it doesn't require greater cognitive capacity. And I don't believe that. Yeah, very good point. Kris, let me ask you a question about how you and your colleagues at Children and Screens set priorities because there are a lot of things that one could potentially worry about as outcomes. There's violence that kids see on social media. There's cognitive and brain development, social developments, social interactions, and bullying. Mental health, body image, diet, all these things are out there. How do you decide what to work on? Well, we try to work on all of it. And in fact, we've built up a fair amount of expertise and resources around almost 25 different topics. And we also understand that, you know, childhood is a long period of time. Birth to 18, birth to 21, birth to 25, depending on who you talk to. So, we're able to take those 25 topics and also provide deeper, you might say, resources that address the different stages of development. We're really trying to do as much as we can. What's been interesting over these last few years is trying to figure out when to be reactive, when to be proactive. And by being proactive, we go out looking for the research, translating it, digesting it, and creating materials with it that we think are really accessible and actionable. At the same time, as Dimitri points out, there are policy windows and there are opportunities that present themselves that you have to react to. If you just only talk about what you want to talk about to each other you're missing some of these external opportunities to inform policy and policy makers. Help influence the way that parents and providers are talking about the issue. Framing it in such a way that engages youth and makes them want what we want for them. We're really excited by increasing opportunities to partner in coalitions with others that care about kids and teachers and nurses and doctors. But we also are speaking directly to leaders in states and school districts at the federal level, at the local level. You would be, I'm sure, not surprised to hear that we are contacted every day by groups that support parents and families. Asking for resources, asking for support, because they're seeing the impact now over many years on their children, their development. Their academic ability. Their cognitive and analytical ability. Their social emotional ability. Their ability to pay attention to tasks that we all know are critical in building that foundation for essentially, you know, future success. The Institute is being pulled in many directions. Ee try really hard to be strategic about what are people asking us for? What does the research say and how can we get that to them as quickly as possible? Dimitri - Can I add to that? You know, I want to emphasize that the concern around the effects of screen use on children's lives is shared by parents on both sides of the aisle. 75% of parents are concerned about the impact of screens on their children's lives. 35% of teenagers are concerned about their dependents on screens and that it has a negative effect on their lives. Actually by some studies, some surveys, even more than 35 to 50% of teenagers are concerned. And both sides of the political aisle agree in large part of this. And Kris and Kelly, you guys are the policy wonks, you can speak more to that. So it's a serious indictment on us as grownups and as a society that we have not done more to deliver on this issue. Why? When there's bipartisan agreement amongst many policymakers. This is not a political [00:22:00] issue to speak of and there is widespread concern on the part of parents and even teenagers. Why is nothing happening? Well, one has to look no further than where the money is. And that's a problem. I mean, that's a serious indictment on our political system when we can't deliver something that is needed and basically wanted by everybody but the industry itself. We'll come back and talk in a few moments about the policy issues and where industry gets involved here. But let me take just a bit of a detour from that and talk about the book that I mentioned earlier, because I think it's such a valuable resource. Now, when I mention the name of this book I'm urging our listeners to write this down or to remember it because you can get the book at no cost. And I'll come back, Kris, and explain what made that possible and why the decision was to make this an open access book. But Dimitri, let's begin with you. So you, along with Lauren Hale, edited this book that's entitled, The Handbook of Children and Screens: Digital Media Development and Wellbeing From Birth Through Adolescence. I think it's an extraordinary piece of work, but tell, tell us about the book.  It was an extraordinary undertaking. There's I think 178 or 180 authors. Literally, it's a who's who of experts in children and media research in all disciplines. It represents pediatrics, psychiatry, psychology, communications experts, demography, lawyers, neuroscientists. I don't know who I'm forgetting. Every single discipline is represented. Leading scientists in all of those areas. Virtually every topic that someone might be of interest to people. And we deliberately made the chapters short and easily accessible. So, it is, I think, a great resource for the constituents we serve. For teachers, for parents, for researchers, for policymakers. And it is free. The hardest part of it, to be honest, as an editor, was getting peer reviewers because unfortunately, every expert was conflicted since they all had an article in it. But it was a long time coming. And again, this was really the brainchild of Pam (Pamela Hurst-Della Pietra) and we're grateful to have brought it along. So, you go all the way from the neuroscience, how children's brains are reacting to this, all the way out there into the public policy and legal arena about what can be done about it. And then kind of everything in between. It's remarkable how much the book covers. It's almost a thousand pages. I mean, it is a tome to be sure. And don't forget to mention, Dimitri, we aren't even two months post publication, and we have 1.6 million views of the document, despite its gargantuan size. I think that is really a tribute to experts like you and others that have really studied this issue and can speak directly to its impacts. It's been great to see the success so far. You know, not a small number of those views is from me logging on. And then a million from me and then we got there. So, it is free because it's online and you can download it. You can also order a hard copy for I think, $60, but I'm not sure why you would do that if you can download it for free. But it's up to you. So, Kris, it's unusual for a book like this to be made open access and free to the general public. What made that possible and why was that so important? We want the maximum number of people to use it and treat it like the premier resource that it is. And the only way you can really do that is to fund it to be open access and find a publisher that does open access publishing, which we did with Springer. I mean, most journal articles are behind a paywall and publishers do require you to purchase either a subscription or the document itself to download it or order it. And we just really wanted maximum access. So, we funded it to be published in that way. And I think honestly, it helped us even sort of create it in the first place. People want to be a part of something that has that level of access and is available so widely. So, I think it was a kind of mutually beneficial. It gets more people to read it, but it got more people to write for it too, I think. Right, Dimitri? Dimitri - I agree. I mean, you know, the numbers 1.6 million are extraordinary. I mean, Kelly, you've been internal editor. I mean, as a editor of JAMA Pediatrics, if an article gets 70,000 views, it's in our top 1%, you know, 200,000 views is 0.01%. 1.6 million in growing is really extraordinary. And that's about the number of people that read my articles. 1.6. And of course, they're not all scientists. I mean, many of them are parents and maybe are policy makers, but that's Kris's point, you know. The moment anyone hits a paywall, even if it's a dollar or two, they're going to walk away. It's great to see it get so much traction. Alright, so again, for our listeners, the title of the book is The Handbook of Children and Screens. And it's really a terrific resource. Alright, so let's turn our attention to a really important matter. And we've sort of touched on this, but who's in charge of protecting our children? You know, Dimitri at the end of the day help survey this landscape for us. I mean, is it congress, is it the administrative branch of government? What role do the courts play? Are there legal actors taking meaningful action? What's being done does it come anywhere near, meeting the need. Tell us about what that landscape is like? Well, there isn't adequate protections for children. And we talked a little bit about that earlier. There's been an enormous loophole, unfortunately, created by Congress when they added the Section 230 to the Communications Decency Act in 1996. And that was put in place essentially to provide protections for internet companies. And it basically said that they should be treated like bookstores and not publishers. That they weren't responsible for content they were just conveying it. And what that means, in effect, was that the companies had sort of carte blanche to do whatever they want. And they've used that very effectively, legally, to argue that any restriction, any culpability on their part, is protected by that Act. That they're exonified for any ill that occurs as a result of their product. The only exception that's been made of it, to date, was around sex trafficking on back page, if anyone remembers that. But other than that, social media sites and internet sites in general have been able to say that they're not liable for anything that's done. And I think that was a huge mistake that was made. It needs to be rectified. It's being challenged in the courts presently. My own belief is that, and I'm not speaking as a lawyer, is that when that law was passed, it was under the assumption as I said, that they were just conveying information. No one at the time foresaw the development of algorithms that would feed the information. It's really not a bookstore when you are making recommendations. Once you start recommending things, I think you're no longer merely a purveyor of product. You're actually pushing it. So, Kris, tell us about the Children and Screens and the role the organization plays in this space. And how do you deal with policy and is it possible to be bipartisan? Yeah, I mean, it's essential. There's no way to get anything done, anywhere on these policy matters at a population level without working in a bipartisan or non-partisan manner, which is what we've always done. And it's easy to do that when you're following the science, not ideology. And you're putting the science first and you're creating resources and tools and support for those mostly staffers, honestly, that are trying to help their bosses get smarter and better at talking about these issues as they evolve and become more complicated over time. It takes more effort to staff a lawmaker on this front. And they're very anxious to learn and understand because they're meeting with parents of children who have been harmed. Or frankly didn't even survive their childhood because of the social media platform. There's great urgency on the part of policymakers. We've heard everything from school phone bans to outright social media bans proposed as policies. And one thing I like to come back to is it's one thing to want to take action and make your best guess at what would have the best impact. But it's another thing to study whether or not that policy actually achieved its result. And it's a part of this that by staying bipartisan, nonpartisan allows us to say, 'Hey lawmaker, if you're able to get that to happen, we'd really like to come in and help study whether or not your idea actually achieves the results that you wanted, or if it needs to be adjusted or amended over time.' Fantastic. That's so important to be doing that work, and I'm delighted the organization is doing it. Let me ask a question here. If you think about some of the areas of public health that I've been following, like tobacco, for example. Opioids more recently. Vaping products. And in the case of my own particular work food policy. The administrative legislative branches of government have been almost completely ineffective. If I think about food policy over the years, relatively little has been accomplished. Even though lots of people have worked really hard on it. Same thing happened with tobacco for many years. Opioids, same thing.  And it's until you get the third branch of government involved, the judiciary, and you start suing the actors who were causing the harm do you get much action. Not only do the lawsuits seem to have an effect, but they soften the ground for legislative things that then can occur because public opinion has changed. And then those things help make a difference as well. What do you think about that kind of issue in this space?  I think you're exactly right. I mean, I think the failure of our legislative branch to enact policy leaves us with very few options at this point anyway, except to try to pursue it through the judiciary. There are challenges there. First and foremost, it's a big and well-funded industry, not unlike tobacco or big food, as you mentioned and there's this Section 230 that's given them kind of blanket immunity to date. But there are many, many very large pending cases in several jurisdictions brought by individuals, brought by school districts, brought by states. And those, at least provisionally have gotten further than prior cases have with which have been thrown out based on Section 230. So, we'll see what happens with that litigation. But right now, my guess is it's the best chance we have to set some guardrails. And I think there are plenty of guardrails that could be set. Everything that these companies have done to make their products addictive can be undone. Can be made protective. The tobacco company deliberately designed their products to be addictive. While they tried to make the claims that they were less addictive, you know. They made light cigarettes that had holes in the filter so that it would diffuse the carbon and nicotine, but people quickly learned they could cover those up with their fingers and think they were smoking light cigarettes, and smoke more of them. There's a lot of things that can be done in this space to undesign the problematic nature of the products. And quite apart from the financial settlements, which will get companies attention, I hope that that's part of any settlement if it gets that far. It'll be interesting to see where those go. And, also historically, one important part of these lawsuits is what gets turned up in discovery. And what sort of intent the companies have and how much do they know about harms. And how much do they know about addiction and things like that. And how they might have proceeded in the face of that information that then doesn't get disclosed to the public. In any event, we'll see where that goes. Dimitri, what about the argument that responsibility resides with parents. It's up to parents to protect their kids from this, and government doesn't need to be involved. I've never understood that argument. I mean parents obviously are children's most important safeguard, but as a society, we enact policies and laws to assist parents in that. I mean to me, if I made the argument, well, why, why do we have minimum ages of drinking. It's parents' job to make sure their kids don't drink. How would that possibly play out? Look, it's hard enough as a parent anyway, because kids do get around these laws. But we still have them and it's a lot easier as a parent. I think most parents would agree their life's made easier by minimum age restrictions on certain things. We have seatbelt laws. I mean, why do we have seatbelt laws? Why don't we just tell its parents' job to make sure their kids buckle up? The truth is its society and parents working hand in hand to try and keep children safe. And I think it also helps parents to be able to say that there are laws around this, and I expect you to follow the laws. So, I don't think it's an either or. Okay, well, I think that's a very good way to frame it. There are many, many precedents where we protect children. And why not do it here too? So let me end with a question I'd like to ask both of you. So, in this sea of concerns that we've discussed, is there a reason for optimism? And Kris, let me start, start with you. What do you think? Absolutely. I think the young people I've met that are leading among their peers are incredibly impressive and are armed with the research and their energy and their own lived experience in ways that are very compelling. At the same time, I think the vast amount of research that has now been compiled and translated and acted upon, whether in courtrooms or in state houses, it's becoming more, and we're all getting more steeped and aware of more nuanced information. And finally, I would just say, there is a tipping point. We are reaching as a society, adults and kids alike, we are reaching a tipping point where we can't withstand the pressure of technology in every aspect, every corner of our day, our life. And we want relief. We deserve relief. And I think that's what's going to take us over the finish line. Good. Well, I'm glad to hear those optimistic notes. Dimitri, what about you? I can find reasons to be optimistic. I mean, look, the reality is that technologies have enriched our lives in many ways. And I think if we put guardrails in place, we can make sure that future ones do even better. I have a piece coming out in JAMA Pediatrics around the use of AI, which people are very concerned about, I think rightly. But specifically, about the use of AI and people with intellectual developmental disabilities, making the use case, that there are ways in which it could be extremely beneficial to that population. A population I care deeply about in my role as the Chief Health Officer at Special Olympics International. And in particular, let's say in terms of the doctor patient interaction where it could facilitate their communication with their provider, and it could also help the provider better communicate with them. Look, that use case isn't going to be a priority for the purveyors of artificial intelligence. It's a small, non-lucrative use of a technology. But it's a good one. And if we created the right incentives and put in the right guardrails, we could find many other ways that technology can serve the needs of all of us going forward. I think the problem is that we've tended to be reactive rather than proactive. And to not start with the do no harm first premise, particularly when it comes to children. AI is another example of that where I hope we don't make the same mistake we made with social media. Bios Kris Perry is the executive director of the Children and Screens Institute. Kris most recently served as Senior Advisor to Governor Gavin Newsom of California and Deputy Secretary of the California Health and Human Services Agency where she led the development of the California Master Plan for Early Learning and Care and the expansion of access to high-quality early childhood programs. She led systems change efforts at the local, state and national levels in her roles as executive director of First 5 San Mateo, First 5 California and of the First Five Years Fund. Through it all, Perry has fought to protect children, improve and expand early learning programs, and increase investments in low-income children. Perry was instrumental in returning marriage equality to California after the landmark 2013 U.S. Supreme Court ruling Hollingsworth v. Perry, which she wrote about in her book Love on Trial (Roaring Forties Press, 2017). Dimitri Christakis, MD, MPH is the Children and Screens Institute's inaugural Chief Science Officer. He is also the George Adkins Professor at the University of Washington, Editor in Chief of JAMA Pediatrics, and the Chief Health Officer at Special Olympics International. Christakis is a leading expert on how media affects child health and development. He has published over 270 peer reviewed articles (h-index 101) including dozens of media-related studies and co-authored a groundbreaking book, The Elephant in the Living Room: Make Television Work for Your Kids. His work has been featured on Anderson Cooper 360, the Today Show, ABC, NBC, and CBS news as well as all major national newspapers. Christakis received his undergraduate degree at Yale University and his medical training at the University of Pennsylvania School of Medicine and completed his residency and Robert Wood Johnson Clinical Scholar Fellowship at the University of Washington School of Medicine. 

What if the key to reversing chronic disease, slowing cognitive decline, and boosting energy lies in the tiny powerhouses inside your cells—and we've finally found a way to protect them? We know mitochondria power our cells, but did you know they also create oxidative stress as they generate energy? Protecting mitochondrial health is critical—but most antioxidants can't reach inside the mitochondria where protection is needed most—until now. MitoQ, a scientifically advanced, mitochondria-targeted antioxidant developed by visionary researchers in New Zealand penetrates mitochondria up to 90%, offering protection where it's needed most. In this episode with Dr. Siobhan Mitchell, we dive into how MitoQ is transforming the way we tackle chronic disease, inflammation, and cognitive decline. From improving heart health to supporting brain function, MitoQ is changing the game. It's something I'm using personally and recommending to most of my patients. Listen in to discover how this powerful tool can help you support your patients at the cellular level—before symptoms even appear. ~DrKF Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources. GUEST DETAILS Dr Siobhan Mitchell, PhD., MitoQ Chief Scientific Officer Email: smitchell@mitoq.com Holding a PhD in neuroscience from SUNY Albany, Siobhan Mitchell has also completed a post-doctoral fellowship on brain aging at the University of Washington. She has over 15 years of clinical research experience, seven patents on mood and cognitive food products, and has authored over 50 papers on aging, brain health, nutrition, metabolic health and more. With a personal passion for brain aging research, Siobhan has worked on metabolic and skin health, appetite, sports physiology and of cellular health –which she now focuses on as the Chief Scientific Officer for research-backed cellular health company, MitoQ – creators of the world's first mitochondria-targeted antioxidant. THANKS TO OUR SPONSOR MitoQ: https://www.mitoQ.com/partner CustomerService@mitoq.com OFFER FOR NEW FRONTIERS LISTENERS Practitioners - Sign up to become a MitoQ Partner, access wholesale rates, and Unlock Cellular Health for your Patients by going to https://www.mitoq.com/partner CONNECT WITH DrKF Want more? Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

Dr. Hoffman continues his conversation with Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics, makers of NTFactor.

Being a pharmacist is exciting–as long as you're willing to try new things. These are wise words from my returning guest on today's podcast, who has been paving the way for integrative pharmacy. Dr. Swathi Varanasi is an award-winning pharmacist passionate about the intersection of personalized medicine, patient outcomes, and innovation. With experience spanning patient care, biotech, research, academia, and consumer product goods, Dr. Swathi has paved the way for healthcare professionals to pursue non-traditional career paths through creating postdoctoral training programs, industry internships, and online educational programs. She co-founded and serves as Chief Scientific Officer of the Life Sciences Division at Element Apothec, and serves as a Principal Investigator at contract research organization, Citruslabs. Dr. Swathi received her Doctor of Pharmacy (PharmD) at the Medical University of South Carolina and Bachelor of Arts (BA) at Carleton College. She was the first-ever pharmacist in the United States with formal residency training to specialize in integrative medicine and preventative health. She also completed a postdoctoral fellowship in Medical Affairs in biotech and has training in nutrition from Cornell University. Dr. Swathi has served as faculty and guest lectures at colleges and universities across the country. She is an advisor and consultant for a number of for-profit and nonprofit organizations aiming to make the world a healthier place for us to live–and thrive. She has been published in peer-reviewed academic journals and featured in Yahoo, mindbodygreen, Well+Good, Entrepreneur, Forbes Health, and more. In 2023, Dr. Swathi was voted one of the 50 Most Influential Leaders in Pharmacy. Connect with Dr. Swathi via: Email: swathimvaranasi@gmail.com FB: Doctor Swathi IG: @doctorswathi Linked In:Dr. Swathi Varanasi Check out our earlier episode here: https://www.marinabuksov.com/s03e03-paving-the-unconventional-path-with-integrative-pharmacist-dr-swathi-varanasi/ Visit https://marinabuksov.com for more holistic content. Music from https://www.purple-planet.com. Disclaimer: Statements herein have not been evaluated by the Food and Drug Administration. Products listed are not intended to diagnose, treat, cure, or prevent any diseases.

Dr. Drew is LIVE in Washington, DC, interviewing members of the Trump admin team including Sec. Robert F. Kennedy Jr, Karoline Leavitt, May Mailman, Sec. Linda McMahon. He's joined by special guest Dr. Peter McCullough. Dr. Peter McCullough is an internist, cardiologist, epidemiologist, and the Chief Scientific Officer at The Wellness Company. As an expert on cardiovascular medicine with over 30 years of experience, Dr. McCullough has spoken widely about the heart-related risks of mRNA. He is the co-author of The Courage To Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex. Follow Dr. McCullough at https://x.com/P_McCulloughMD and learn more at https://PeterMcCulloughMD.com Dr. Stephanie Venn-Watson is a co-founder of Seraphina Therapeutics. She holds a Doctor of Veterinary Medicine from Tufts University, a Master of Public Health from Emory University, and completed a National Research Council Associateship with the Armed Forces Medical Intelligence Center. As a Technical Agent for DARPA and researcher with the U.S. Navy Marine Mammal Program, she discovered C15:0's role in preventing Cellular Fragility Syndrome. This led her to co-found Seraphina Therapeutics, developing the fatty15 supplement. Find more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com AI is revolutionizing healthcare by offering new ways to solve complex problems, emphasizing data-driven solutions over traditional hypothesis-based approaches. In this episode, Dr. Sam Perli, Chief Scientific Officer and founding member of Thinkhat, discusses how his company is building an AI-powered venture studio to launch innovative healthcare and life sciences companies. Thinkhat serves physicians with its Noki co-pilot for automated tasks, patients with noninvasive monitoring solutions, and pharmaceutical companies with its Encode AI engine for optimizing sequence medicines. Dr. Perli acknowledges skepticism around AI but highlights its potential to solve complex problems like protein folding and neurodegenerative diseases. He encourages openness to AI and suggests cost-effective development strategies, including tapping into global talent pools and leveraging resources in places like Puerto Rico. Tune in and learn how Thinkhat leverages AI to address previously unsolvable problems in medicine, providing a diverse set of solutions across the healthcare industry! Resources:  Connect and follow Dr. Sam Perli on LinkedIn. Learn more about Thinkhat on their LinkedIn and website. Email Thinkhat directly here. Email Sam here. Fast Track Your Business Growth: Outcomes Rocket is a full-service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com

Dr. Eric Kmiec is Director of the Gene Editing Institute of the Helen F. Graham Cancer and Research Institute at Christiana Care Health System. He also holds faculty appointments at the University of Delaware and the Wistar Institute. Eric and his colleagues are working to develop new ways to treat cancer by destroying the genes that cause cancer cells to be resistant to typical therapies like chemotherapy, radiation, or immunotherapy. Throughout his life, Eric has enjoyed sports. He particularly likes playing baseball and hockey, and he still plays baseball competitively in a league in Philadelphia. Eric also spends much of his time doing landscaping and yard work. He Received his B.A. in Microbiology from Rutgers University, his M.S. in Cell Biology and Biochemistry from Southern Illinois University, and his Ph.D. in Molecular Biology and Biochemistry from the University of Florida School of Medicine. He conducted postdoctoral research at the University of Rochester before joining the faculty at the University of California, Davis in 1987. Since then, he has served on the faculty of Thomas Jefferson University, the University of Delaware, and Delaware State University. In addition, Eric founded, consulted for, and served as Vice President of Kimeragen, Inc., he was Chief Scientific Advisor for the Genomics Division of Tapestry Pharmaceuticals, was an Eminent Scholar and Director of the Marshall University Institute for Interdisciplinary Research, and also served as Co-Founder, Chief Scientific Officer, and a Board Member of OrphageniX. Eric has received numerous awards and honors over the course of his career, including receipt of the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease, designation as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in 2013 and 2014, and also induction into the Southern Illinois University, Edwardsville Alumni Hall of Fame in 2012. Further, Eric and the team at the Gene Editing Institute were recently awarded the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce. In our interview, Eric shared his experiences in life and science.

Join me for a fascinating conversation around an exciting breakthrough in dementia detection that's offering real hope for early intervention. Dr. Hans Frykman, Chief Scientific Officer at Neurocode Laboratories, is here to share groundbreaking insights into cutting-edge biomarkers that can identify pathology associated with Alzheimer's disease before symptoms even appear. What's even more fascinating is how these same tools are revealing neuroinflammation caused by infections, including COVID, Lyme disease, and mold exposure—issues that are incredibly relevant in functional medicine today. The assays Dr. Frykman and his team have developed, and continue to research, are transforming the way we think about diagnosing and addressing neurodegeneration. We're talking about a potential game-changer that allows us to intervene earlier, reverse damage, and ultimately improve the trajectory of these conditions. This is an extraordinary time in science and medicine, and the work we're discussing today is at the forefront of it all. Don't miss out on how this could reshape your practice. ~DrKF Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources. GUEST DETAILS Dr. Hans Frykman, MD PhD FRCPC hfrykman@neurocode.com Hans Frykman MD, Ph.D., FRCPC is the founder, CEO, and medical director of BC Neuroimmunology Lab located in the UBC hospital on the University of BC campus in Vancouver BC. He is the medical director for Lykke Lab a genetics laboratory also on the University of BC campus. Also, he is the CSO for Neurocode Lab Inc. in Bellingham WA, a high-complexity, specialty lab focused on neuroimmunology and biomarkers in neurodegeneration. Dr. Frykman has a clinical faculty position at the University of British Columbia, Faculty of Medicine, Division of Neurology. THANK YOU TO OUR SPONSORS DIAMOND DUTCH: https://dutchtest.com/for-providers Biotics Research: https://www.bioticsresearch.com/ GOLD TimeLine Nutrition: https://tinyurl.com/bdzx2xms Vibrant Wellness: https://www.vibrant-wellness.com/ EXCLUSIVE OFFERS FROM OUR SPONSORS OneSkin: Get 15% off OneSkin with the code DRKARA at oneskin.co/DRKARA Try Qualia NAD+ for up to 50% off! Visit http://qualialife.com/kara15 and use code KARA15 at checkout for an additional 15% off your entire purchase! Why MitoQ's mitochondria-targeting is a critical step for your healthspan and longevity strategy. https://tinyurl.com/2b5benmd Want more? CONNECT WITH DrKF Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

In this episode of Skin Anarchy, we sit down with Dr. Jérémie Soeur, Chief Scientific Officer, and Jennifer Hessel, General Manager of North America at Cellcosmet, to explore how cutting-edge research is redefining skincare. With a science-first approach, Cellcosmet is setting new standards in microbiome support, peptide technology, and cellular rejuvenation.Dr. Soeur explains how Cellcosmet's CytoPEP™ technology harnesses over 5,000 peptides, proteins, amino acids, and enzymes to target multiple skin-aging pathways. Unlike brands that rely on isolated ingredients, Cellcosmet's approach activates a network of biological functions to restore skin vitality. Their CellControl™ method ensures the peptides retain their structure and effectiveness throughout formulation, a step often overlooked in traditional skincare.Jennifer Hessel highlights the importance of microbiome research, explaining how Cellcosmet sequences bacteria before and after product use to measure its real impact on skin health. Their formulations not only nourish the microbiome but also protect against environmental stressors, making them a true game-changer in skincare.What sets Swiss skincare apart? Stringent quality control. Cellcosmet follows some of the world's strictest regulations, maintaining 100 times lower microbial contamination levels than standard beauty products, ensuring pharmaceutical-grade purity.As skincare personalization continues to evolve, Cellcosmet is pioneering the future—using microbiome sequencing and epigenetic research to develop tailored solutions for individual skin needs.Tune in to hear how science is driving the next era of beauty and why Cellcosmet is revolutionizing the way we think about skincare.SHOP Cellcosmet and use code SAcellcosmet15 for 15% off your first purchase!To learn more about Cellcosmet, visit their website and social media. Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Hosted by Mike Simmons. In this episode of #BigImpactAstronomy, Mike Simmons talks with Olayinka Fagbemiro about her inspiring work bringing STEM education to underserved communities in Nigeria. From IDP camps to classrooms, she's empowering young minds—especially girls—to see a future in science.    (From the Karman Project) Olayinka Fagbemiro has dedicated over 17 years to advancing space science and technology as the Chief Scientific Officer at the Nigerian Space Agency. She currently leads the Space Education Outreach Unit and is a vital member of the Planning, Policy, and Research team.  Her leadership extends to her role as the Founder, CEO and National Coordinator, Astronomers Without Borders Nigeria, an NGO leveraging astronomy to foster STEM education and address educational inequalities across Nigeria. Olayinka is pursuing a PhD in Geoinformatics at the African University of Science and Technology, where her research focuses on the use of deep learning algorithms for urban development studies. Her expertise in spatial sciences is further augmented by her academic background, with a B.Sc. in Computer Science from the University of Ilorin and an M.Sc. in Technology Management from Obafemi Awolowo University.   Mike Simmons is the founder of Astronomy for Equity ( https://bmsis.org/astro4equity/ ). Others on the team, including people around the world in astronomy and space exploration, authors and philosophers, designers and artists and more will be added as the website is developed.   We've added a new way to donate to 365 Days of Astronomy to support editing, hosting, and production costs.  Just visit: https://www.patreon.com/365DaysOfAstronomy and donate as much as you can! Share the podcast with your friends and send the Patreon link to them too!  Every bit helps! Thank you! ------------------------------------ Do go visit http://www.redbubble.com/people/CosmoQuestX/shop for cool Astronomy Cast and CosmoQuest t-shirts, coffee mugs and other awesomeness! http://cosmoquest.org/Donate This show is made possible through your donations.  Thank you! (Haven't donated? It's not too late! Just click!) ------------------------------------ The 365 Days of Astronomy Podcast is produced by the Planetary Science Institute. http://www.psi.edu Visit us on the web at 365DaysOfAstronomy.org or email us at info@365DaysOfAstronomy.org.

Have you ever considered silver as a line of treatment?  Not only can topical silver-based products help with wound healing, but there's actually a TON of immune-boosting benefits from taking colloidal silver, too.  Expert and leader at Silver Biotics– Steve Revelli joins me today to show you how silver is redefining health, energy, and strength for so many people.  You already know I'm a big proponent of preventative medicine, especially when it comes to lowering inflammation, supporting gut and whole-body health, and healing our bodies naturally and effectively...  And silver products can help us do just that!  Silver Biotics has tons of diverse products that boost immune system health and benefit the whole body.  So check out the podcast here to discover the massive advantages of using silver, and grab a discount for your first order of Silver Biotics!  Steve Revelli Steve Revelli is the Chief Scientific Officer and R&D leader at American Biotech Labs. He's also a retired educator and former Adjunct Professor, bringing 30+ years of science and health education to his role. At Silver Biotics, he pioneers clean cosmetics and wound care products, merging science with wellness. IN THIS EPISODE What is colloidal silver, and how does it work? How silver is used in modern science and medicine Silver technology's interaction with the immune system  The importance of supplementation- particularly for women during midlife Unpacking myths around the use of colloidal silver  The future technology and uses of silver in medicine  Using silver for acute conditions or preventative measures  About Silver Biotics, and their effective supplements and products  QUOTES “What happens is you give an immune supplement that takes care of all the bioload and allows the immune system to do what it normally does and function a lot more efficiently, and that's what our silver does.” “What the immune system support does with our silver is it takes care of those pathogens. So you can have a good, healthy population of probiotics always in your gut.”  “The immune support that the silver does– it kills pathogens. It'll kill pathogens anywhere in the body.” RESOURCES MENTIONED Get Your Silver Biotics HERE ++ use code: DRMARIZA for 30% off your first order! Silver Biotics on Instagram  Silver Biotics on Facebook  RELATED EPISODES  #610: The Benefits of Spirulina and Chlorella for More Energy, Longevity, And Immunity with Catharine Arnston 591: Post Viral Syndromes, Your Immune System, And Your Hormones in Midlife with Dr. Jessica Drummond #334: 3 Immune-Boosting Habits That Are Non-Negotiable Right Now